Patents by Inventor John P. Hennessey, Jr.

John P. Hennessey, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and kits for use in preventing and treating vulvovaginal candidiasis
    Patent number: 10857216
    Abstract: The invention features methods and kits use in for preventing and treating vulvovaginal candidiasis (VVC), in particular, recurrent VVC.
    Type: Grant
    Filed: March 7, 2017
    Date of Patent: December 8, 2020
    Assignees: NovaDigm Therapeutics, Inc., Los Angeles Biomedical Institute at Harbor-UCLA Medical Center
    Inventors: John E. Edwards, Jr., Scott G. Filler, John P. Hennessey, Jr., Michael Timothy Cooke, Jack D. Sobel
  • Methods and compositions for vaccinating against
    Patent number: 10653757
    Abstract: The invention features a method of vaccinating a mammal against Staphylococcus aureus which includes the steps of: a) identifying a mammal at risk for the development of a Staphylococcus aureus skin or soft tissue infection; and b) administering to said mammal an immunogenic amount of a vaccine that includes a polypeptide including an isolated agglutinin-like sequence (Als) 3 protein (Als3p), or an immunogenic fragment thereof, in a pharmaceutically acceptable medium.
    Type: Grant
    Filed: July 20, 2012
    Date of Patent: May 19, 2020
    Assignees: NovaDigm Therapeutics, Inc., Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
    Inventors: Michael R. Yeaman, John E. Edwards, Jr., Scott G. Filler, Ashraf S. Ibrahim, Yue Fu, John P. Hennessey, Jr.
  • METHODS AND KITS FOR USE IN PREVENTING AND TREATING VULVOVAGINAL CANDIDIASIS
    Publication number: 20190076512
    Abstract: The invention features methods and kits use in for preventing and treating vulvovaginal candidiasis (VVC), in particular, recurrent VVC.
    Type: Application
    Filed: March 7, 2017
    Publication date: March 14, 2019
    Inventors: John E. EDWARDS, JR., Scott G. FILLER, John P. HENNESSEY, JR., Michael Timothy COOKE, Jack D. SOBEL
  • COMPOSITIONS AND METHODS FOR TREATING FUNGAL AND BACTERIAL PATHOGENS
    Publication number: 20190030141
    Abstract: The invention features fragments of the Candida cell surface proteins Als3 and Hyr1 and combinations thereof useful in immunizing a subject against fungal or bacterial infections or both.
    Type: Application
    Filed: October 11, 2018
    Publication date: January 31, 2019
    Inventors: Ashraf S. Ibrahim, Michael R. Yeaman, Scott G. Filler, John E. Edwards, JR., John P. Hennessey, JR.
  • Compositions and methods for treating fungal and bacterial pathogens
    Patent number: 10130691
    Abstract: The invention features fragments of the Candida cell surface proteins Als3 and Hyr1 and combinations thereof useful in immunizing a subject against fungal or bacterial infections or both.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: November 20, 2018
    Assignees: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, NovaDigm Therapeutics, Inc.
    Inventors: Ashraf S. Ibrahim, Michael R. Yeaman, Scott G. Filler, John E. Edwards, Jr., John P. Hennessey, Jr.
  • COMPOSITIONS AND METHODS FOR TREATING FUNGAL AND BACTERIAL PATHOGENS
    Publication number: 20160030534
    Abstract: The invention features fragments of the Candida cell surface proteins Als3 and Hyr1 and combinations thereof useful in immunizing a subject against fungal or bacterial infections or both.
    Type: Application
    Filed: March 14, 2014
    Publication date: February 4, 2016
    Applicants: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, NovaDigm Therapeutics, Inc.
    Inventors: Ashraf S. IBRAHIM, Michael R. YEAMAN, Scott G. FILLER, John E. EDWARDS, JR., John P. HENNESSEY, JR.
  • METHODS AND COMPOSITIONS FOR VACCINATING AGAINST STAPHYLOCOCCUS AUREUS
    Publication number: 20150273031
    Abstract: The invention features a method of vaccinating a mammal against Staphylococcus aureus which includes the steps of: a) identifying a mammal at risk for the development of a Staphylococcus aureus skin or soft tissue infection; and b) administering to said mammal an immunogenic amount of a vaccine that includes a polypeptide including an isolated agglutinin-like sequence (Als) 3 protein (Als3p), or an immunogenic fragment thereof, in a pharmaceutically acceptable medium.
    Type: Application
    Filed: July 20, 2012
    Publication date: October 1, 2015
    Applicants: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, NovaDigm Therapeutics, Inc.
    Inventors: Michael R. Yeaman, John E. Edwards, JR., Scott G. Filler, Ashraf S. Ibrahim, Yue Fu, John P. Hennessey, JR.
  • Process for making capsular polysaccharides from Streptococcus pneumoniae
    Patent number: 5847112
    Abstract: Type-specific capsular polysaccharide preparations from Streptococcus pneumoniae, having on average less than about 1000 oligosaccharide repeat units per molecule, polydispersities between 1.0 and 1.4, intrinsic viscosities between 0.6 and 3.0 dL/g, and less than 3% contamination of type-specific polysaccharide by group-specific C-polysaccharide, are produced by a novel process. The novel type specific polysaccharide products are useful in the preparation of vaccines, especially covalent conjugates comprising the novel polysaccharide linked to a T-cell stimulatory carrier protein. Vaccines comprising the novel polysaccharides are useful in the prevention of infection and of diseases associated with infection by Streptococcus pneumoniae.
    Type: Grant
    Filed: November 14, 1997
    Date of Patent: December 8, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Peter J. Kniskern, William J. Miller, Arpi Hagopian, Charlotte C. Ip, John P. Hennessey, Jr., Dennis J. Kubek, Pamela D. Burke
  • Pneumococcal polysaccharide conjugate vaccine
    Patent number: 5623057
    Abstract: A novel conjugate vaccine comprising partially hydrolyzed, highly purified, capsular polysaccharide (Ps) from Streptococcus pneumoniae bacteria (pneumococci, Pn) linked to an immunogenic carrier protein, is produced by a new process. The conjugate is useful in the prevention of pneumococcal infections. Vaccines comprising a mixture of from one to ten different pneumococcal polysaccharide-immunogenic protein (Pn-Ps-PRO) conjugates induce broadly protective recipient immune responses against the cognate pathogens from which the polysaccharide components are derived. Young children and infants younger than 2 years old, normally unable to mount a protective immune response to the Pn-Ps alone, exhibit protective immune responses upon vaccination with these Pn-Ps-PRO conjugates.
    Type: Grant
    Filed: May 20, 1994
    Date of Patent: April 22, 1997
    Assignee: Merck & Co., Inc.
    Inventors: Stephen Marburg, Richard L. Tolman, Peter J. Kniskern, William J. Miller, Arpi Hagopian, Charlotte C. Ip, John P. Hennessey, Jr., Dennis J. Kubek, Pamela D. Burke